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Atrial fibrillation (AFib) is the most common arrhythmia and is responsible for significant morbidity and mortal-
ity in patients with heart failure (HF) with reduced ejection 
fraction (HFrEF) or preserved ejection fraction (HFpEF).1,2 
There is a reciprocal relationship between HF and AFib 
in which HF predisposes to AFib and AFib worsens HF.3–5 
Much is known about the role of AFib in HFrEF but studies 
of AFib in HFpEF are more limited. Some recent clinical trial 
and observational studies have shown that AFib is present in 
≤43% of patients with HFpEF and is perhaps more prevalent 
than in HFrEF.2,3,5–8
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Studies of patients with HFpEF have shown that the pres-
ence of AFib on an ECG is independently associated with a 
higher incidence of cardiovascular morbidity.2,7
Recent studies have indicated that periodic ECGs may miss 
several patients who are at risk from AFib.9,10 A history of 
AFib may help identify some of these at-risk patients. The 
primary objective of this post hoc analysis of data from the 
Irbesartan in Heart Failure with Preserved Ejection Fraction 
Trial (I-PRESERVE) was to determine whether a history of 
AFib is an independent risk factor for stroke in patients with 
HFpEF.
Methods
Study Design and Patient Selection
I-PRESERVE is a randomized, placebo-controlled, double-blind, 
multicenter trial that enrolled subjects with symptomatic HFpEF to 
evaluate the efficacy of the angiotensin receptor blocker irbesartan.11 
Briefly, 4128 patients, ≥60 years with symptomatic (New York Heart 
Association class II–IV) HF with a left ventricular (LV) ejection 
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Background—Atrial fibrillation (AFib) is common in heart failure (HF) with preserved ejection fraction (HFpEF). Current 
AFib stroke risk prediction models include the presence of HF but do not specifically include HFpEF as a risk factor. 
Whether a history of AFib should be used to identify patients with HFpEF who are at risk has not been established.
Methods and Results—Baseline characteristics and outcomes of patients with HFpEF in the Irbesartan in Heart Failure with Preserved 
Ejection Fraction Trial were analyzed in relation to AFib. At baseline, 1209 (29.3%) had a history of AFib. Of these 557 (13.5%) 
had history of AFib alone, whereas 670 (16.2%) had both a history and AFib on ECG; 2901 (70.3%) had neither. There were no 
significant differences in the risk of stroke between the 2 groups with a history of AFib who did or did not have AFib present on 
baseline ECG. During a median follow-up of 53 months, a fatal or nonfatal stroke occurred in 6.5% (79/1209) patients with history 
of AFib compared with 3.9% (114/2901) with no AFib. Having a history of AFib was independently associated with higher risk of 
stroke (hazard ratio, 2.2; 95% confidence interval, 1.6–3.2; P<0.0001) compared with those with no history of AFib.
Conclusions—In patients with HFpEF, a history of AFib was common and independently associated with increased risk of 
stroke, regardless of whether AFib was present on ECG. Patients with HFpEF and a history of AFib should be considered 
at risk. Further studies are needed to determine whether this risk can be safely reduced.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.   
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fraction >45%, and ≥1 hospitalization for HF during the previous 6 
months were eligible to be enrolled. Patients who had not been hospi-
talized were required to have ongoing class III or IV symptoms with 
corroborative evidence of HF, or a likely substrate for HFpEF, such 
as electrocardiographic or echocardiographic evidence of moderate 
or severe LV hypertrophy or left atrial enlargement in the absence 
of AFib. The primary end point of the study was the composite of 
all-cause mortality and protocol-specified cardiovascular hospitaliza-
tions. There were several secondary end points including all-cause 
mortality, cardiovascular death or HF hospitalization, and HF death 
or HF hospitalization (HF composite end point). Deaths and hospital-
izations were adjudicated by a blinded independent end point com-
mittee, using prespecified criteria. Eligible patients were randomized 
to receive irbesartan or placebo in a 1:1 ratio stratified by site and use 
of an angiotensin-converting enzyme inhibitor at baseline. The study 
was approved by the institutional review board at each center, and all 
subjects provided a written informed consent.
This analysis focused on patients classified as at risk based on the 
history of AFib in the case report forms with or without AFib docu-
mented on the required baseline ECG. The following study outcomes 
were analyzed in these groups and compared with the group that had 
neither a history or ECG indicating AFib: fatal or nonfatal stroke, 
cardiovascular death or HF hospitalization, HF death or HF hospital-
ization, and all-cause mortality.
Statistical Analysis
The baseline characteristics of subjects with a history of AFib with 
or without AFib at baseline on their ECG and those without any in-
dication of AFib were compared with each other using ANOVA for 
continuous variables or cross-tabulation for categorical variables with 
a Bonferroni correction for multiple pairwise comparisons when the 
overall P value was significant. Distributions of the natriuretic peptide 
levels were positively skewed and were transformed using logarithms 
for analysis. Unadjusted Kaplan–Meier curves are shown to describe 
the study outcomes in each group. Because the investigational medi-
cation, irbesartan did not have a significant effect on any of the study 
end points, all enrolled subjects were included in this analysis.
Cox regression analyses were used to estimate hazard ratios for 
each of the study outcomes for the 2 distinct groups with a history 
of AFib, those with or without AFib also present on their baseline 
ECG, as well as both of these groups combined compared with the 
group with no history or ECG record of having AFib. The 2 groups 
with a history of AFib were compared with each other by simply 
changing the reference group for the AFib group indicator variable 
in the Cox regression analyses. Because all but 18 (2.7%) of the 670 
subjects that had AFib on their baseline ECG also had a history of 
AFib, we included these 18 patients whose history was most likely 
misclassified in the group with both a history of AFib and AFib 
on ECG. The results were not substantially different when these 
18 subjects were excluded from all groups (not reported). Adjusted 
hazard ratios were estimated by multivariable Cox regression in-
cluding age at baseline, sex, race, history of ischemic heart disease, 
chronic obstructive pulmonary disease, hypertension, hyperlipid-
emia, stroke, renal artery disease, diabetes mellitus, hospitalization 
for HF in previous 6 months, heart block, and other arrhythmias, 
chronic kidney disease, anemia, systolic blood pressure, LV hy-
pertrophy on ECG, albumin, platelet count, and treatment with ir-
besartan, antiarrhythmic, antiplatelet agent, antithrombotic agent, 
calcium channel blocker, β-blocker, angiotensin-converting enzyme 
inhibitor, digoxin, diuretic, spironolactone, nitrate, lipid-lowering 
drugs, and an implantable cardioverter defibrillator/pacemaker. 
Several clinical variables that could be affected by the presence of 
ongoing AFib at baseline including pulmonary congestion on x-
ray, rales, jugular venous distention, liver enlargement, New York 
Heart Association class, heart rate, and natriuretic peptide were not 
included in these multivariable regression analyses to avoid over 
adjustment for potential mediators of the effects of AFib on study 
outcomes. The proportional hazards assumption for each variable 
and outcome was examined using Schoenfeld residuals. Stata soft-
ware version 12.1 was used for all analyses.
Results
Baseline Characteristics in Relation to AFib 
Indicators
A history of AFib was present in 29% (1209/4128) of the 
patients, and in approximately half of these (670/1209) AFib 
was documented on baseline ECG. There was no history or 
ECG documentation of AFib in 2901 of the 4128 patients.
Baseline characteristics of the 3 groups defined by AFib 
indicators are summarized in Table 1. The groups with or 
without AFib on their baseline ECG were similar except for 
several signs and symptoms of decompensated HF, cardiac 
rhythm disturbances, ischemic heart disease, and medications. 
Both groups with indicators of AFib differed from those with-
out AFib on several variables.
Association Between Indicators of AFib and 
Outcomes
During a median follow-up of 53 months (interquartile range, 
41–60 months), fatal or nonfatal stroke occurred in 5.7% 
(38/670) patients with history and AFib on ECG compared 
with 7.4% (41/557) with history of AFib alone and in 3.9% 
(114/2901) with no AFib (Figure [A]), cardiovascular death 
or HF hospitalization occurred in 45% (302/670) patients with 
history and AFib on ECG compared with 54% (298/557) with 
history of AFib alone and in 35% (1021/2901) with no AFib 
(Figure [B]); the HF death or HF hospitalization composite end 
point occurred in 29% (196/670) patients with history and AFib 
on ECG compared with 26% (146/557) with history of AFib 
alone and in 13% (367/2901) with no AFib (Figure [C]); 30% 
(203/670) patients with history and ECG evidence of AFib died 
from any cause compared with 28% (156/557) with history of 
AFib alone and 18% (515/2901) with no AFib (Figure [D]).
Table 2 shows the unadjusted and adjusted comparisons of 
study outcomes in AFib indicator groups. Except for a higher 
risk of HF hospitalizations or death in the group with AFib on 
baseline ECG, there were no significant differences in the out-
comes between the 2 AFib groups defined by ECG. As shown in 
Table 1, the group with AFib on baseline ECG had more signs 
and symptoms of HF as expected and these variables were not 
included in the adjustment model (see Statistical Analysis sec-
tion). The increased risk of stroke was significant and simi-
lar in the groups with or without AFib on the baseline ECG. 
Combining these 2 groups, the adjusted estimate of the increase 
in the risk of fatal or nonfatal stroke associated with a history 
of AFib was hazard ratio 2.2 (95% confidence interval, 1.6–3.2) 
compared with the group with no indication of AFib. A history 
of AFib was significantly associated with cardiovascular death 
or HF hospitalization, 1.2 (1.0–1.4) and HF death or HF hospi-
talization 1.3 (1.1–1.6) but not with all-cause mortality.
Discussion
In this analysis of I-PRESERVE we found that although 29% 
patients had a history of AFib at baseline, AFib was confirmed 
on ECG in only half (54%) of them (16% of total cohort), and 
the remaining patients (14% of the cohort) had a history of 
AFib alone. The presence of AFib on the baseline ECG did not 
increase the significant risk of stroke associated with a history 
of AFib. To the best of our knowledge this is the first report to 
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Table 1. Baseline Characteristics in Groups With and Without Indicators of Atrial Fibrillation
None History Only History and ECG
P Value
Overall AFib Groups*
No. of subjects 2901 (70%) 557 (14%) 670 (16%) ... ...
Age, mean (SD), y 71 (6.8) 73 (6.6) 74 (7.1) <0.0001 NS
Men, n (%) 1091 (38) 238 (43) 308 (46) <0.0001 NS
Nonwhite (%) 92 97 97 <0.0001 NS
Hypertension, n (%) 2609 (90) 480 (86) 561 (84) <0.0001 NS
Diabetes mellitus, n (%) 785 (27) 159 (29) 182 (28) 0.73 ND
Hyperlipidemia, n (%) 1328 (46) 255 (46) 227 (34) <0.0001 <0.0001
Ischemic heart disease, n (%) 1565 (54) 274 (50) 257 (39) <0.0001 <0.0001
Stroke/TIA, n (%) 243 (8.4) 75 (14) 81 (12) <0.0001 NS
Renal artery disease (%) 10.2 3.0 2.4 0.002 NS
COPD/asthma, n (%) 237 (8.2) 87 (16) 67 (10) <0.0001 0.009
Valve disease, n (%) 216 (7.5) 109 (20) 126 (19) <0.0001 NS
Other arrhythmia, n (%) 337 (12) 99 (18) 57 (8.5) <0.0001 <0.0001
Heart block, n (%) 54 (1.9) 30 (5.4) 16 (2.4) <0.0001 0.02
Pacemaker/ICD implanted, n (%) 102 (3.5) 91 (16) 71 (11) <0.0001 0.04
HF admission in past 6 mo for HF, n (%) 1073 (37) 332 (60) 411 (62) <0.0001 NS
Hypertensive HF etiology, n (%) 1933 (66.6) 320 (58) 359 (55) <0.0001 NS
Ischemic HF etiology, n (%) 771 (27) 135 (24) 130 (19) 0.001 NS
Diastolic blood pressure, mean (SD), mm Hg 79 (8.9) 77 (9.5) 79 (9.4) 0.0003 NS
Systolic blood pressure, mean (SD), mm Hg 137 (14) 136 (17) 134 (15) <0.0001 NS
Heart rate, mean (SD) 71 (9.8) 70 (11) 76 (12) <0.0001 <0.0001
JVD, n (%) 204 (7.0) 39 (7.0) 103 (16) <0.0001 <0.0001
Liver enlargement, n (%) 533 (18) 81 (14) 139 (21) 0.014 0.015
Rales, n (%) 790 (27) 142 (25) 226 (34) 0.002 0.006
Left ventricular hypertrophy, n (%) 938 (32) 163 (29) 159 (24) <0.0001 NS
Left bundle-branch block, n (%) 244 (8.4) 48 (8.6) 44 (6.6) 0.28 ND
Pulmonary congestion on chest radiograph, n (%) 999 (36) 244 (45) 347 (54) <0.0001 0.006
Left ventricle EF %, mean (SD) 60 (9.1) 59 (8.9) 58 (9.3) <0.0001 NS
Left atrial area, cm2, mean (SD)† 21.3 (5.0) 25.3 (6.6) 29.7 (6.3) <0.0001 <0.0001
eGFR, mean (SD), mL/min 74 (22) 69 (23) 69 (21) <0.0001 NS
CKD, n (%) 795 (27.7) 219 (40.0) 229 (35.7) <0.0001 NS
NT-proBNP, median (IQR), pg/mL 230 (104–538) 534 (232–1118) 1319 (776–2062) <0.0001 <0.0001
Irbesartan, n (%) 1455 (50) 267 (48) 345 (51) 0.37 ND
ACE inhibitor, n (%) 696 (24) 154 (28) 183 (27) 0.08 ND
Antiplatelet, n (%) 1893 (65) 294 (53) 229 (34) <0.0001 <0.0001
Antiarrhythmic, n (%) 99 (3.4) 178 (32) 82 (12) <0.0001 <0.0001
Anticoagulant, n (%) 128 (4.4) 230 (41) 432 (64) <0.0001 <0.0001
β-blocker, n (%) 1714 (59) 321 (58) 392 (58) 0.80 ND
Calcium channel blocker, n (%) 1221 (42) 194 (35) 222 (33) <0.0001 NS
Diuretic, n (%) 2307 (80) 485 (87) 626 (93) <0.0001 <0.0001
Lipid lowering, n (%) 936 (32) 174 (31) 169 (25) 0.002 NS
Digoxin, n (%) 131 (4.5) 108 (19) 322 (48) <0.0001 <0.0001
Nitrate, n (%) 828 (29) 134 (24) 146 (22) 0.001 NS
Spironolactone, n (%) 358 (12) 110 (20) 165 (25) <0.0001 NS
ACE indicates angiotensin-converting enzyme; AFib, atrial fibrillation; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; eGFR, estimated 
glomerular filtration rate; EF, ejection fraction; HF, heart failure; ICD, implantable cardioverter defibrillator; IQR, interquartile range; JVD, jugular venous distension; ND, 
not done because overall not significant; NS, not significant with Bonferroni correction for possible 3 pairwise comparisons; NT-proBNP, N-terminal pro B natriuretic 
peptide; and TIA, transient ischemic attack.
*Comparing the 2 groups that did or did not have AFib on baseline ECG if overall ANOVA P value was <0.01. 
†Left atrial area was measured in 696 subjects only.
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highlight this finding in patients with HFpEF. Although the risk 
associated with AFib on ECG in patients with HFpEF has been 
examined previously,2,7,12–15 this analysis indicates that a history 
of AFib is also associated with an increased risk of cardiovas-
cular morbidity and mortality, including stroke. These results, 
therefore, suggest that a history of AFib should be taken into 
consideration when assessing the risks of AFib in patients with 
HFpEF regardless of whether AFib is present on ECG.
Although it is well known that AFib increases the risk of isch-
emic stroke in patients with HFrEF, only a few recent studies 
have reported that the risk of stroke is also increased in patients 
with HFpEF.2,7,12–14,16 Studies have compared the risk of stroke 
in patients with AFib and HFrEF or HFpEF. A subgroup analy-
sis of the AFib Follow up Investigation of Rhythm Management 
(AFFIRM) trial found that although the history of stroke was 
more prevalent in patients with HFpEF compared with HFrEF 
at baseline (16% versus 11%), the subsequent incidence of 
stroke during the study was no different between the groups.17 
The Candesartan in Heart failure-Assessment of Reduction in 
Mortality and morbidity (CHARM) study also did not find a 
difference in the incidence of stroke in patients with AFib with 
either HFrEF or HFpEF.7 In patients with preexisting AFib, 
McManus et al2 reported a 91% higher risk of ischemic stroke in 
HFpEF and only 7% higher risk in HFrEF compared with those 
without AFib. The most recent data come from the post hoc anal-
yses of the new oral anticoagulant trials such as ARISTOTLE 
(Apixaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation Trial),12 ROCKET (Rivaroxaban 
Once daily oral direct factor Xa inhibition Compared with vita-
min K antagonism for prevention of stroke and Embolism Trial 
in atrial fibrillation),13 and RE-LY (Randomized Evaluation of 
Long-term anticoagulation therapY with dabigatran etexilate).14 
These studies show that although the risk of stroke or systemic 
embolism was significantly higher in patients with a diagnosis 
of HF compared with those with no HF, the risk of stroke or sys-
temic embolism was no different in patients with HF with pre-
served or reduced ejection fraction. These data suggest that the 
risk of stroke in patients with AFib and HFpEF is at least as high 
as those in patients with AFib and HFrEF and that the guidelines 
should specifically emphasize the inclusion of all patients with 
HF in the CHADS2 (congestive HF, hypertension, age, diabe-
tes mellitus, and prior stroke or transient ischemic attack) and 
CHA2DS2-VASc scoring system, irrespective of the ejection 
fraction. Furthermore, our data suggest that the same guidelines 
should also apply to patients with HFpEF even when they only 
have a history of AFib that is not confirmed on ECG.
The original CHADS2 score designed to help estimate the 
risk of stroke and need of anticoagulation in patients with non-
valvular AFib was based on studies in patients with HF with 
LV dysfunction.18 Accordingly, the 2006 and 2011 American 
College of Cardiology/American Heart Association/Heart 
Rhythm Society AFib clinical practice guidelines recom-
mended the use of CHADS2 score as a guide to anticoagula-
tion of patients with AFib and HF with impaired LV systolic 
function but did not mention HFpEF.19,20 The most recent 
European Society of Cardiology AFib 2012 guidelines recom-
mend the use of CHA2DS2-VASc instead of the CHADS2 score 
and define HF as documented moderate-to-severe systolic dys-
function or patients with recent decompensated heart failure 
requiring hospitalization, irrespective of ejection fraction but 
do not include stable patients with HFpEF.21 The 2 most recent 
HF guidelines also do not specifically mention HFpEF. The 
Figure.  Kaplan–Meier curves for time to fatal or nonfatal stroke (A), cardiovascular death or heart failure (HF) hospitalization (B), HF 
death or HF hospitalization (C), and all-cause mortality (D) in groups defined by a history of atrial fibrillation (AFib), a history of AFib con-
firmed by ECG or no indication of AFib.
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2012 European Society of Cardiology HF guideline endorses 
thromboembolic prophylaxis in patients with HF and AFib 
based on the CHA2DS2-VASc score, defining HF as conges-
tive HF or LV ejection fraction <40%,22 and the most recent, 
2013 American College of Cardiology Foundation/American 
Heart Association HF guideline recommends the use of antico-
agulant in patients with chronic heart failure with permanent, 
persistent, or paroxysmal AF and an additional risk for cardio-
embolic stroke.1 Hence, although the intent of the guidelines 
might have been to include all patients with HF irrespective of 
LV ejection fraction, the written document may be ambiguous 
and clinicians may not be entirely clear on this issue.
Strengths and Limitations
This analysis is based on the largest randomized clinical 
trial of well-characterized patients with HFpEF where all 
outcomes were adjudicated. In addition, we were able to 
examine AFib separately by history alone and AFib confirmed 
by ECG along with several established prognostic variables, 
including comorbidities, clinical examination and laboratory 
data, and medication use. However, this is a secondary analy-
sis of data from a randomized controlled trial and some of the 
findings may be spurious although the results are consistent 
with previous studies. The results may not be widely appli-
cable. For example, I-PRESERVE subjects with HFpEF were 
predominantly white and the results may not be generalizable 
to other racial groups. The presence of AFib was assessed at 
baseline by a single ECG. However, this limitation is unlikely 
to change our conclusions because the outcomes were similar 
in those with history of AFib not confirmed on ECG. Indeed, a 
history of AFib seemed to be sufficient to increase the risk and 
captured nearly all of the patients with AFib on ECG. Because 
Table 2. Comparison of Outcomes in Atrial Fibrillation Indicator Groups
Outcome Unadjusted HR (95% CI; n=4128) Adjusted* HR (95% CI; n=3942)
Fatal or nonfatal stroke 
  History of AFib without AFib on ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib with AFib on ECG 0.94 (0.62–1.44) 1.16 (0.72–1.86)
  No AFib on history or baseline ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib without AFib on ECG 1.97 (1.38–2.81) 2.12 (1.40–3.21)†
  History of AFib with AFib on ECG 1.85 (1.31–2.61) 2.45 (1.54–3.92)†
  Combined groups with history of AFib 1.90 (1.44–2.52)† 2.24 (1.55–3.24)†
CV death/HF hospitalization
  History of AFib without AFib on ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib with AFib on ECG 0.86 (0.73–1.00) 0.92 (0.76–1.09)
  No AFib on history or baseline ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib without AFib on ECG 1.81 (1.59–2.06)† 1.23 (1.05–1.44)‡
  History of AFib with AFib on ECG 1.55 (1.36–1.76)† 1.13 (0.94–1.34)
  Combined groups with history of AFib 1.67 (1.51–1.84)† 1.19 (1.03–1.37)‡
HF death/HF hospitalization
  History of AFib without AFib on ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib with AFib on ECG 1.23 (0.99–1.52) 1.28 (1.01–1.64)‡
  No AFib on history or baseline ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib without AFib on ECG 2.29 (1.89–2.78)† 1.18 (0.93–1.50)
  History of AFib with AFib on ECG 2.82 (2.37–3.35)† 1.51 (1.19–1.92)‡
  Combined groups with history of AFib 2.57 (2.22–2.98)† 1.32 (1.08–1.63)‡
All-cause mortality
  History of AFib without AFib on ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib with AFib on ECG 1.18 (0.96–1.45) 1.14 (0.90–1.44)
  No AFib on history or baseline ECG 1.00 (reference group) 1.00 (reference group)
  History of AFib without AFib on ECG 1.66 (1.39–1.98)† 1.07 (0.86–1.34)
  History of AFib with AFib on ECG 1.95 (1.66–2.29)† 1.23 (0.99–1.54)
  Combined groups with history of AFib 1.82 (1.59–2.06)† 1.15 (0.95–1.38)
AFib indicates atrial fibrillation; CI, confidence interval; CV death, cardiovascular death; HF, heart failure; and HR, hazard ratio.
*Adjusted for age, sex, race, history of ischemic heart disease, renal artery disease, chronic obstructive pulmonary disease, hypertension, 
hyperlipidemia, stroke, diabetes mellitus, HF hospitalization in past 6 months, heart block, other arrhythmias, chronic kidney disease, 
anemia, systolic blood pressure, left ventricular hypertrophy (ECG), albumin, platelets, treatment with irbesartan, antiarrhythmic, antiplatelet, 
antithrombotic, calcium channel blocker, β-blocker, angiotensin-converting enzyme inhibitor, digoxin, diuretic, spironolactone, nitrate, 
lipid-lowering drugs, implantable cardioverter defibrillator, and pacemaker.
†P<0.001; ‡ P<0.01.
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we did not have data on patients with HFrEF including sets of 
covariates, comparisons of the different types of HF could not 
be made as some previous studies have done.
In conclusion, in this sample of patients with HFpEF, a his-
tory of AFib was common and independently associated with 
increased risk of fatal or nonfatal stroke. The presence of AFib 
on ECG did not significantly heighten the risk. Patients with 
HFpEF and a history of AFib should be considered at risk of 
stroke, and HFpEF should be included as a risk factor in stroke 
prediction models for patients with AFib. Future studies are 
needed to determine whether this risk can be safely reduced.
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CLINICAL PERSPECTIVE
Atrial fibrillation (AFib) is common in patients with heart failure (HF) and reduced or preserved ejection fraction. The cur-
rent AFib stroke risk prediction guidelines include the presence of HF but do not specifically mention HF with preserved 
ejection fraction as a risk factor. Moreover, most risk assessment studies have used ECG to identify patients with AFib. 
Whether a history of AFib should also be used to identify patients with HF with preserved ejection fraction who are at risk 
from AFib has not been established. Our analysis of the 4128 patients in Irbesartan in Heart Failure with Preserved Ejection 
Fraction Trial (I-PRESERVE) showed that 29% of the patients had a history of AFib, whereas only 16% had both a history 
and AFib on ECG. There were no significant differences in the risk of stroke between the 2 groups with a history of AFib. 
A history of AFib was independently associated with >2-fold increase in the risk of stroke, regardless of whether AFib was 
present on ECG. Patients with HF with preserved ejection fraction and a history of AFib should be considered at risk. Further 
studies are needed to determine whether this risk can be safely reduced. 
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